Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Nanosensing Technologies Developed for Exosome Detection and Profiling

By LabMedica International staff writers
Posted on 20 Nov 2019
Exosomes are extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells. More...
Liquid biopsy technologies have been developed to do high-throughput exosome protein profiling and point-of-care (POC) exosome analysis.

The aim is to develop multiplexed assay systems to streamline the analysis of exosomes and evaluate their clinical utility for cancer management, both as diagnostic tools and to predict disease recurrence. Nanoplasmonic sensors are fabricated to accommodate at most one exosome and individually imaged in real time, enabling the label-free recording of digital responses in a highly multiplexed geometry.

Scientists at the Massachusetts General Hospital (MGH, Boston, MA, USA) and their colleagues developed the nano-plasmonic exosome (nPLEX) sensor, in routine use at MGH, which detects exosome protein levels based on “spectral shifts” (intensity changes) of light through thousands of optimally spaced 200-nanometer (nm) holes. Antibodies against cancer biomarkers get immobilized on the nanopores for capture.

Nanoholes on the sensor are gold and exosomes are labeled by gold nanoparticles for signal amplification. Gold has proven to have the best chemical stability for this type of assay. The device is being manufactured on a glass-based substrate, as silicon wafers proved to be too fragile. The iMEX (integrated magnetic-electrochemical exosome) device, meanwhile, integrates vesicle isolation and detection in a single platform. Target-specific exosomes first get enriched through immunomagnetic selection, for high detection sensitivity. The sensors can be miniaturized and expanded for parallel measurements.

The nPLEX has demonstrated good accuracy and 100 times greater sensitivity than the commonly used enzyme-linked immunosorbent assay (ELISA) and able to detect as few as 3,000 exosomes. The team has also come up with a protein signature for pancreatic ductal adenocarcinoma (PDAC) that is powerful enough for diagnostic purposes, a combination of EGFR (epidermal growth factor receptor), EpCAM, MUC1, GPC1 and WNT2. As demonstrated in a prospective study involving more than 100 patients and age-matched controls, as the tumors shrink the biomarker combination gets lower and lower.

The scientists have also used nPLEX technology to show how exosome protein expression of cancer cells changes with drug treatment. Discovery of these unique, drug-dependent protein signatures suggests the exosome screening assay will be a potentially powerful molecular screening tool. Hyungsoon Im, PhD, an assistant professor of radiology and a senior author of the study, said, “The screening assay could be incorporated into point–of–care (POC) instruments for more rigorous testing of different drugs in different settings. The study was presented at the 2019 Next Generation Dx Summit held August 20-22, 2019 in Washington, DC, USA.

Related Links:
Massachusetts General Hospital


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.